Khalifa E Sharquie, Adil A Noaimi, Adel R Bandar and Salah Y Mohsin
Background: Vitiligo is common autoimmune pigmentary disorders where there are no cutaneous cancers have been reported among affected patients. Objective: To estimate the frequency P53 marker and its role in protection against skin cancers in patients with vitiligo. Patients and Methods: This study took place in the Department of Dermatology, Baghdad Hospital during the period from May 2009-September 2010. It is composed of two parts: Part I was case descriptive study performed to record any association of skin malignancies in 300 vitiligo patients, 155 females and 145 males, while Part II was case observational, controlled, histochemical, investigative study to estimate the frequency of P53 in vitiliginous skin and adjacent normal skin in comparison with control group. Skin biopsies were taken from 25 patients, one from the centre of vitiliginous patch and the other about 0.5 cm adjacent to the patch (normal skin). Skin biopsies were also done for 25 individuals as a control group. Results: Regarding Part I of the study, no malignant skin diseases like basal cell carcinoma, squamous cell carcinoma or malignant melanoma were found in the present work. In Part II of this work, the positivity of P53 in normal skin was 32%, while in adjacent normal skin was 84% and in vitiliginous skin was 96%. Conclusions: P53 marker is over expressed in vitiligo skin and this might give it protection against skin cancers
この記事をシェアする
English 
Spanish 
Chinese 
Russian 
German 
French 
Portuguese 
Hindi 